Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders
US7820711B2 · kind B2 · utility
5Cited by
3References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 2007 |
| Grant date | Oct 26, 2010 |
| Priority date | — |
| Expiry date | Jun 11, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.